Golcadomide

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaFollicular LymphomaNon-Hodgkin LymphomaLarge B-Cell LymphomaLymphoma, FollicularRelapsed/refractory Non-Hodgkin LymphomaKidney Failure, Chronic

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Golcadomide

Bristol-Myers Squibb

Phase 3

52

Zofran

Novartis

Preclinical

23

Norvir

AbbVie

Preclinical

14

Cabenuva

GSK

Preclinical

15

Nuvigil

NNuvo Research GmbH

Preclinical

16

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

17

Kenalog

BBausch Health Americas, Inc.

Preclinical

18

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1Show 34 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Lymphoma5 trials

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recruiting·MMayo Clinic·Phase 2·NCT06834373·41 enrolled

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 1/2·NCT07018752·49 enrolled

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Not yet recruiting·NNatalie Galanina·Phase 1/2·NCT06767956·30 enrolled

Show 2 more trials

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Recruiting·NNathan Denlinger·Phase 1·NCT06209619·18 enrolled

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT06271057·65 enrolled

Follicular Lymphoma2 trials

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting·Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Active, not recruiting·OOlivia Newton-John Cancer Research Institute·Phase 2·NCT05788081·40 enrolled

Large B-cell Lymphoma2 trials

Phase I Pilot Trial of Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas

Not yet recruiting·AAllison Winter·Phase 1·NCT07608731·18 enrolled

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Active, not recruiting·Bristol-Myers Squibb·Phase 3·NCT06356129·850 enrolled

Drug1 trial

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT06363630·35 enrolled

Relapsed/Refractory Non-Hodgkin Lymphoma1 trial

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)

Recruiting·Bristol-Myers Squibb·Preclinical·NCT06090539·460 enrolled

3 more indications

Non-Hodgkin Lymphoma1 trial

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma

Active, not recruiting·Roche·Phase 1·NCT05169515·121 enrolled

Kidney Failure, Chronic1 trial

A Phase 1, Multi-center, Single-dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of Golcadomide (BMS-986369) in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

Not yet recruiting·Bristol-Myers Squibb·Phase 1·NCT07763418·30 enrolled

Lymphoma, Follicular1 trial

A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Active, not recruiting·Bristol-Myers Squibb·Phase 2·NCT06425302·95 enrolled

Details

Drug Info

Related News